NCI Definition: An adenocarcinoma that arises from the male or female urethra. 
Urethral adenocarcinomas most frequently harbor alterations in TP53 .
TP53 Mutation are the most common alterations in urethral adenocarcinoma .
There are 2 clinical trials for urethral adenocarcinoma, of which 2 are open and 0 are completed or closed. Of the trials that contain urethral adenocarcinoma as an inclusion criterion, 2 are phase 2 (2 open).
Durvalumab, nivolumab, and tremelimumab are the most common interventions in urethral adenocarcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.